Humana reports 3Q26 EPS of $1.33 and raises 2026 guidance

Item 7.01 Regulation FD Disclosure.

Humana Inc. (the "Company") issued a press release this morning reporting financial results for the quarter ended September 30, 2026, and posted a detailed earnings release related to the same period to the Investor Relations portion of the Company's website at www.humana.com . A copy of each release is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and each release is incorporated herein by reference. Additionally, a copy of management's prepared remarks on the Company's financial results for the quarter ended September 30, 2026 and expectations for future earnings, is attached hereto as Exhibit 99.3, and incorporated herein by reference.¹

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No. Description

99.1 Press Release

99.2 Earnings Release and Statistical Pages

99.3 Prepared Management Remarks

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMANA INC.

BY: /s/ John-Paul W. Felter

John-Paul W. Felter

Senior Vice President, Chief Accounting Officer & Controller

(Principal Accounting Officer)

Dated: November 6, 2026

n e w s r e l e a s e

Exhibit 99.1

Humana Inc.

101 East Main Street

P.O. Box 1438

Louisville, KY 40202

http://www.humana.com

FOR MORE INFORMATION CONTACT:

Lisa Stoner

Humana Investor Relations

(502) 580-2652

e-mail: LStamper@humana.com

Mark Taylor

Humana Corporate Communications

(317) 753-0345

e-mail: MTaylor108@humana.com

Humana Reports Third Quarter 2026 Financial Results;

Raises Full Year 2026 Adjusted EPS Guidance

• Continued strategic expansion of the company's CenterWell and Medicaid footprints

◦ YTD growth of 146,800 patients, or 30 percent, in CenterWell Senior Primary Care

◦ Recently announced joint venture (JV) with BlackRock replaced the previous JVs with Welsh, Carson, Anderson & Stowe, enhancing balance sheet efficiency and providing greater financial flexibility at a reduced cost of capital, while also funding future growth²

◦ YTD Medicaid membership growth of 103,600, or 7 percent, largely driven by the start of integrated Duals programs in Michigan, Illinois, and South Carolina³

• Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 8:00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings

LOUISVILLE, KY (November 6, 2026) – Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share for the quarter ended September 30, 2026 (3Q26) versus the quarter ended September 30, 2025 (3Q25) and for the nine months ended September 30, 2026 (YTD 2026) versus the nine months ended September 30, 2025 (YTD 2025) as noted in the tables below.

1

Consolidated income (loss) before income taxes and equity in net losses (pretax results) In millions

Impact of exit of employer group commercial medical products business — (62) — (62)

Settlement of certain litigation expenses — 15 — 15

Loss on sale of business — 63 — 63

Impact of exit of employer group commercial medical products business — (0.52) — (0.52)

Settlement of certain litigation expenses — 0.13 — 0.13

Loss on sale of business — 0.52 — 0.52

Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.

Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-year quarterly and YTD comparisons.

"Humana is delivering positive results for our members, our patients and their health," said Humana President and CEO Jim Rechtin. "We are also increasingly driving financial and operating performance toward being 'ahead' of our plan."

FY 2026 Earnings Guidance

Humana revises its GAAP EPS guidance for the year ending December 31, 2026 (FY 2026) to 'at least $15.09' from 'at least $6.52', while raising its Adjusted EPS guidance to 'at least $9.50' from the previous guidance of 'at least $9.00'. The FY 2026 Adjusted EPS guidance anticipates a year-over-year decline as a result of the Star Ratings headwind for Bonus Year (BY) 2026, net of mitigation.

2

Diluted earnings per share (a)

FY 2026

Guidance FY 2025

GAAP at least $15.09 $9.84

Amortization associated with identifiable intangibles 0.31 0.42

Put/call valuation adjustments associated with the company's non-consolidating minority interest investments (c) (11.42) 4.25

Initial option liability associated with recently announced strategic joint venture with HPS Investment Partners (BlackRock) and CenterWell Senior Primary Care (e) 2.14 —

Impact of exit of employer group commercial medical products business (d) — (0.52)

Settlement of certain litigation expenses (d) — 0.13

Loss on sale of business (d) — 0.55

Cumulative net tax impact